Usted buscó: mcl (Inglés - Danés)

mcl
mcl

elderly mcl patients
Ældre patienter med mcl

mantle cell lymphoma (mcl)
mantle-celle-lymfom (mcl)

mcl dose modification after recovery
Ændring af mcl-dosis efter bedring

description of risk of tumor flare reaction in mcl patients
beskrivelse af risikoen for tumor-flare-reaktion hos mcl-patienter

clinical efficacy in previously untreated mantle cell lymphoma (mcl)
klinisk virkning ved tidligere ubehandlet mantle-celle-lymfom (mcl)

posology for patients with previously untreated mantle cell lymphoma (mcl)
dosering til patienter med tidligere ubehandlet mantle-celle-lymfom (mcl)

additionally, adrs from supportive study mcl-001 have been included in table 3.
desuden er bivirkninger fra det understøttende studie, mcl-001, blevet inkluderet i tabel 3.

this effect has also been observed in about one third of patients with relapsed or refractory mcl treated with imbruvica.
denne effekt er også blevet observeret i omkring en tredjedel af patienterne med recidiverende eller refraktær mcl i behandling med imbruvica.

in study mcl-002, tls was reported for one patient in each of the two treatment arms.
i studie mcl-002 blev tls rapporteret hos én patient i hver af de to behandlingsarme.

in patients with mcl, transient neutropenia that was reversible between cycles was observed, with no evidence of cumulative neutropenia.
hos patienter med mcl blev der observeret forbigående neutropeni, som var reversibel mellem cyklusser og uden evidens for kumulativ neutropeni.

a high number of circulating lymphocytes (> 400,000/mcl) may confer increased risk.
et højt antal cirkulerende lymfocytter (> 400 x 109/l) kan medføre en øget risiko.

in 36 patients with mcl, including 4 poor metabolisers, the effect of cyp2d6 inhibition after administration of single doses of 175 mg and 75 mg temsirolimus was investigated.
effekten af cyp2d6-hæmning efter administration af 175 mg og 75 mg temsirolimus som enkeltdoser er blevet undersøgt hos 36 patienter med mantlecellelymfom, heraf 4 patienter med nedsat metabolisme.

imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl).
imbruvica som monoterapi er indiceret til behandling af voksne patienter med recidiverende eller refraktært mantle-celle-lymfom (mcl).

a large increase in the number of circulating lymphocytes (e.g., > 400,000/mcl) has been observed in some patients.
der er blevet observeret en stor stigning i antallet af cirkulerende lymfocytter (f.eks. > 400 x 109/l) hos visse patienter.